A comprehensive view of Blood Disorders. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Bioeconomy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

European Commission approves Pfizer's DURVEQTIX® gene therapy for hemophilia B; reduces bleeds post-treatment with a median annualized bleed rate of zero bleeds after up to four years of follow-up
Published: July 25, 2024 by Pfizer Inc.
Pfizer advances hemophilia A gene therapy and honors cancer pharmacogenomics research; company also reduces greenhouse gas emissions in Spain and engages Greek pharmacy students for educational visit
Published: July 25, 2024 by Industry Intelligence Inc.
Pfizer announces positive Phase 3 results for hemophilia A gene therapy giroctocogene fitelparvovec; trial shows a significant reduction in mean total annualized bleeding rate
Published: July 24, 2024 by Pfizer Inc.
Pfizer Inc Files Patent Application for Antibodies Specific for FLT3 and Their Uses
Published: July 12, 2024 by Indian Patents News
Novartis Submits Patent Application for Use of an MDM2 Inhibitor for the Treatment of Myelofibrosis
Published: July 03, 2024 by Pharmaceutical Patent News

Ask us about our Bioeconomy market view

Trending Chart

Interactive chart with headline count